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Abstract
Background: Apolipoprotein E (apoE) is a major cholesterol transport protein found in association with brain
amyloid from Alzheimer’s disease (AD) patients and the ε4 allele of apoE is a genetic risk factor for AD. Previous
studies have shown that apoE forms a stable complex with amyloid b (Ab) peptides in vitro and that the state of
apoE lipidation influences the fate of brain Ab, i.e., lipid poor apoE promotes Ab aggregation/deposition while fully
lipidated apoE favors Ab degradation/clearance. In the brain, apoE levels and apoE lipidation are regulated by the
liver X receptors (LXRs).
Results: We investigated the hypothesis that increased apoE levels and lipidation induced by LXR agonists
facilitates Ab efflux from the brain to the cerebral spinal fluid (CSF). We also examined if the brain expression of
major apoE receptors potentially involved in apoE-mediated Ab clearance was altered by LXR agonists. ApoE,
cholesterol, Ab40, and Ab42 levels were all significantly elevated in the CSF of rats after only 3 days of treatment
with LXR agonists. A significant reduction in soluble brain Ab40 levels was also detected after 6 days of LXR
agonist treatment.
Conclusions: Our novel findings suggest that central Ab lowering caused by LXR agonists appears to involve an
apoE/cholesterol-mediated transport of Ab to the CSF and that differences between the apoE isoforms in
mediating this clearance pathway may explain why individuals carrying one or two copies of APOE ε4 have
increased risk for AD.
Background
Alzheimer’s disease (AD) is a neurodegenerative disease
characterized by the progressive loss of memory and
cognitive function [1]. The presence of amyloid-b (Ab)
peptide deposits in the hippocampal and cortical regions
of the brain is a major hallmark of AD pathology. Ab
peptides, mainly Ab40 and Ab42, are released from the
transmembrane amyloid precursor protein (APP) follow-
ing sequential cleavage by b- and g-secretases and have
been shown to cause toxicity to both neurons and glia
cells in vitro and in vivo [1,2]. The most significant
genetic association reported for late-onset AD is with
apolipoprotein E (apoE), the main lipid transporter pro-
tein in the central nervous system (CNS) [3,4]. Three
human apoE isoforms arise from polymorphisms within
the APOE gene, named E2, E3 and E4. While only 15%
of the normal population carries apoE4, up to 70% of
AD patients have one or two copies of apoE4.
The mechanism by which apoE4 increases the risk for
AD is not yet clear. It has been established that both
healthy individuals and AD patients carrying apoE4 have
increased brain amyloid burden [5,6]. Likewise, APP trans-
genic (APP-Tg) mice expressing human apoE4 in replace-
ment of mouse apoE (apoE4 knock-in, KI) have increased
brain amyloid load compared to apoE3 KI mice [7].
Furthermore, it has been previously shown that binding of
apoE to Ab in vitro is isoform- and lipid-dependent [8,9].
When associated with lipids, apoE3 binds Ab more effi-
ciently than apoE4. However, apoE’s ability to bind Ab is
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reduced and the isoform-dependent Ab binding differ-
ences are lost when apoE is lipid-free. Therefore, due to its
ability to bind Ab, particularly the more amyloidogenic
Ab42, apoE appears to play an important role in both the
aggregation and the clearance of Ab within and out of the
brain parenchyma.
In addition to increased brain amyloid load, apoE4 KI
mice have reduced levels of CNS apoE and it has been
postulated that the overall lower levels of apoE protein
may explain the increased amyloid load and risk for AD
in apoE4 carriers [7,10,11]. Astrocyte-secreted apoE4
also has decreased association with lipids when com-
pared to apoE3, a difference that may underlie the
reduced ability of apoE4 to bind Ab and to promote its
clearance [11,12]. The majority of lipids associated with
astrocyte-secreted apoE are contributed by the ATP-
binding cassette protein A1 (ABCA1), and both apoE
and ABCA1 are liver X receptors (LXR)-target genes
[13,14].
LXRa and LXRb are nuclear hormone receptors
involved in lipid metabolism and inflammatory signaling
throughout the body [15]. It has been previously shown
that synthetic LXR agonists regulate the expression of
apoE and ABCA1 in astrocytes suggesting that LXRs play
an important role in the regulation of lipid metabolism in
the CNS [16]. Increased levels of brain ABCA1 and apoE
observed with short-term (6-10 days) and prolonged
(4 months) systemic treatment with synthetic LXR ago-
nists was also associated with reduced brain Ab burden
in mice [17-23]. The mechanism by which LXR activa-
tion reduces brain amyloid appears to be via increased
Ab clearance since APP processing was not altered by
LXR agonist compounds [22,23]. Potential clearance
pathways may involve the endocytosis of Ab/apoE-lipid
complexes via apoE receptors such as the low-density
lipoprotein receptor (LDLR) and the low-density lipopro-
tein receptor-related protein 1 (LRP1), which are highly
expressed in neurons and glia and have been shown to
regulate the overall levels of CNS apoE [24-27]. Other
Ab clearance pathways are through elimination at the
blood-brain barrier (BBB) and the CSF [28,29]. These
pathways are not well understood and may also involve
Ab/apoE-lipid particles binding to apoE receptors.
In the present study, we investigated the modulation of
apoE and Ab levels by LXR agonists in the CSF. Because
this Ab clearance pathway is likely to be saturated in
APP overexpressing mice and CSF samples free of blood
contamination can be difficult to obtain from mice, we
used rats for these studies. We show, for the first time,
that systemic administration of LXR agonists causes a
robust and fast increase in apoE, cholesterol, and endo-
genous Aθ in the CSF of rats. Consistently, LXR agonist
treatment markedly increases the levels of LXR target
genes apoE and ABCA1 in cells of the choroid plexus
and ependyma, suggesting that central engagement of
LXRs may improve the clearance of parenchymal amyloid
to the ventricular system, contributing to the overall
reduction of brain amyloidosis.
Results
Systemic administration of LXR agonists for 6-10 days had
been previously shown to upregulate brain apoE and
reduce Ab levels in both APP transgenic and wild-type
mice [17-23]. Because apoE is abundant in the CSF and
CSF apoE is thought to derive entirely from within the
brain, we sought to investigate the effects of LXR agonist
treatment on CSF apoE and Ab levels. A marked up-
regulation of apoE levels in the CSF was detected by
Western blotting analysis following systemic treatment with
LXR agonists T1317 and GW3965 at 30 mpk (Figure 1A).
This increase was statistically significant after 3 days of dos-
ing and similar to that observed with 6 and 10 days of treat-
ment. Treatment with the more potent full LXR agonist
T1317 produced a larger increase in CSF apoE than the less
potent partial agonist GW3965. Compound levels in the
brain and plasma were also higher for T1317 than for
GW3965 (data not shown), likely contributing to the differ-
ential degree of efficacy of the two compounds. No signifi-
cant changes were observed in the CSF albumin levels.
Soluble apoE levels were also significantly elevated in
the brain following treatment with LXR agonists. DEA-
soluble extracts obtained from the right forebrain (cortex
and hippocampus) were analyzed for apoE content by
Western blotting (Figure 1B). Up-regulation of soluble
apoE was clearly observed after 6 days of dosing, but the
differences were only statistically significant after 10 days
of treatment. This LXR agonist-mediated effect was spe-
cific to apoE as there were no significant changes in the
soluble levels of brain apoJ, which is not directly regu-
lated by LXRs. Consistent with the findings for the CSF,
T1317 showed a more potent effect in increasing soluble
apoE brain levels than GW3965. The delayed increase in
brain apoE when compared to CSF apoE levels was also
observed in the plasma, where elevation in apoE levels
were more evident following 10 days of treatment with
LXR agonists (Figure 1C). In summary, up-regulation of
the LXR target gene apoE was observed in the CSF, the
brain parenchyma and plasma within a few days of sys-
temic administration with LXR agonists.
Because LXR agonists have also been shown to upregu-
late the cholesterol efflux pump ABCA1 in the CNS, we
evaluated total cholesterol levels in CSF samples from
rats treated with LXR agonists in comparison to the vehi-
cle control (Figure 2A). CSF cholesterol was significantly
increased by LXR agonists at all time points examined,
with the greatest change observed after 10 days of dosing
with T1317 (2-fold increase). Interestingly, we observed a
concomitant decrease of cholesterol in the DEA-soluble
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brain fraction of rats treated with T1317 after 3 days of
dosing, which was reversed to normal levels with
extended treatment (Figure 2B). These results are
consistent with the up-regulation of cholesterol synthesis
that follows increased cholesterol efflux induced by LXR
agonists [30].
Figure 1 CSF and brain apoE levels were markedly increased with LXR agonist treatment. The levels of apoE in the CSF, soluble brain
extracts, and plasma following systemic treatment with LXR agonists T1317 and GW3965 at 30 mpk for 3, 6, and 10 days were evaluated by
Western blot analysis as described in Methods. A: Representative blots showing changes in apoE levels in the CSF of rats treated with vehicle or
LXR agonists (left panel). Albumin was used as a loading control for all CSF blots. Densitometric analysis of Western blots for CSF apoE (right
panel). B: DEA extracted soluble brain homogenates were prepared as described in Methods. Equal amounts of supernatant proteins were
loaded per lane and apoJ was used as an additional loading control. Representative blots showing changes in apoE observed in the soluble
brain fraction of rats treated with vehicle, T1317 and GW3965 (left panel). Densitometric analysis of Western blots for soluble brain apoE (right
panel). C: Representative blots showing changes of apoE levels in the plasma of rats treated with vehicle or LXR agonists (left panel).
Densitometric analysis of Western blots for plasma apoE (right panel). *p < 0.05 compared to vehicle treated controls by ANOVA, N = 4 per
group.
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When CSF samples were separated in native gels,
immunoreactivity associate with apoE in T1317 treated
rats was markedly increased in bands at higher molecular
weight than the bands present in the CSF of vehicle con-
trol rats (Figure 2C). While vehicle CSF showed faint
apoE-immunoreactive bands at 240 and around 400 kD
(¬), CSF from T1317-treated animals had strong apoE-
immunoreactivity in bands detected at approximately 400
and 650 kD (◀). These results suggested that larger apoE-
lipid particles were likely present in the rat CSF following
LXR agonist treatment.
We next asked if the increased transport of apoE-
cholesterol to the CSF induced by LXR agonists was
accompanied by increased transport of Ab peptides and
reduced brain amyloid. As shown in Figure 3A, Ab40
and Ab42 levels were significantly increased in the CSF
of rats treated with LXR agonists for 3 days. The effect
was most robust following 6 days of treatment with
T1317 and coincident with a small, but significant
decrease in DEA-soluble brain Ab40 (Figure 3B). DEA-
soluble brain Ab42 was below the minimum detection
level of the Ab rodent ELISA. Taken together, these
results support the hypothesis that apoE-lipid transport
may influences Ab efflux from the brain to the CSF.
Brain levels of the LXR target gene ABCA1 and the
apoE receptors LDLR and very low-density lipoprotein
receptor (VLDLR), which may be directly or indirectly
regulated by LXR, were also examined in detergent
(RIPA) extracts (Figure 4). Consistent with previous
published studies, ABCA1 protein levels were signifi-
cantly increased by LXR agonists at all time points
examined (Figure 4A). Following 10 days of compound
treatment, the steady-state levels of the apoE receptors
LDLR and VLDLR appeared reduced when compared to
that of vehicle controls, but these differences did not
reach statistical significance (Figure 4B).
CSF is secreted by the choroid plexus and by the epen-
dymal cells lining the ventricles [31]. Because LXR ago-
nist-induced changes in CSF apoE appear to occur more
rapidly and at a greater degree than in the brain tissue,
we examined the pattern of apoE and ABCA1 mRNA
expression in the mouse brain by in situ hybridization
following GW3965 treatment (50 mpk for 10 days).
As shown in Figure 5A, both ABCA1 and soluble apoE
Figure 2 CSF and soluble brain cholesterol were inversely altered by LXR agonist treatment. The levels of cholesterol in CSF and soluble
brain extracts were evaluated using the Amplex Red Cholesterol Kit as described in Methods. A: Cholesterol levels in the CSF of rats treated with
LXR agonists in comparison to the vehicle control. B: Cholesterol levels in the DEA-soluble brain fraction of rats treated with LXR agonists in
comparison to the vehicle control. *p < 0.05 compared to vehicle treated controls by ANOVA, N = 4 per group. C: CSF samples were separated
in native gel as described in Methods and then blotted with an anti-apoE antibody. Representative blot showing apoE immunoreactive bands in
the CSF of rats treated with vehicle or T1317 for 3 days. CSF from vehicle-treated rats shows apoE-immunoreactive bands around 240 and 400
kD (¬), while CSF from T1317-treated animals had strongest apoE-immunoreactivity in bands detected at approximately 400 and 650 kD (◀).
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protein levels were significantly elevated in the mouse
brain, similar to the changes observed in the rat brain. By
in situ hybridization, apoE mRNA was very abundant in
the mouse brain and detected in a pattern consistent
with astrocytic expression (Figure 5B). Even though apoE
mRNA was noticeably upregulated throughout the brain
following GW3965 treatment (Figure 5B), the ependyma
region of the lateral ventricles showed a robust up-regu-
lation of apoE mRNA by the LXR agonist (Figure 5C).
ABCA1 mRNA overall distribution was consistent with
both neuronal and astrocytic expression, but similar to
apoE mRNA, up-regulation by GW3965 was also strong
in the choroid plexus and ependyma (Figure 5D). These
findings suggest that a high level of LXR activation in the
choroid plexus and ependymal cells could have led to the
fast and significant up-regulation of apoE and cholesterol
levels observed in the rat CSF following systemic treat-
ment with LXR agonists.
Finally, to corroborate our hypothesis that LXR agonists
increase apoE lipidation in the brain, we examined the
ability of T1317 to increase the release of cholesterol from
a brain relevant cell line to exogenously added apoE. ApoE
particles were generated by transient transfection of the
human apoE3 cDNA into HEK 293 cells. Conditioned
serum-free media from empty vector-transfected HEK
cells was used as control (Figure 6A). Cholesterol-loaded
CCF-STTG1 astrocytoma cells were treated with approxi-
mately 50 μg/ml of apoE3-concentrated media or the
equivalent of total protein from vector-concentrated
media/ml (no detectable apoE) plus 5 μM T1317 or vehi-
cle, and incubated in serum-free media for 48 hours. As
shown in Figure 6B, total cholesterol/protein measured in
the media following incubation with T1317 was signifi-
cantly greater in the apoE3 media than in the vector
media. In addition, T1317 did not stimulate the secretion
of cholesterol to the vector media, suggesting that apoE is
the putative acceptor for the released cholesterol. As
expected, Western blotting of CCF-STTG1 cell lysates
showed marked up-regulation of ABCA1 with T1317
treatment. To further confirm the role of ABCA1 in
Figure 3 CSF Ab levels were increased and soluble brain Ab levels were decreased by LXR agonists. The levels of Ab40 and Ab42 in the
CSF and soluble brain extracts were evaluated by ELISA as described in Methods. A: Ab40 and Ab42 levels in the CSF of rats treated with LXR
agonists in comparison to the vehicle control. B: Ab40 levels in the DEA-soluble brain fraction of rats treated with LXR agonists in comparison to
the vehicle control. *p < 0.05 compared to vehicle treated controls by ANOVA, N = 4 per group.
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lipidating exogenously added apoE3, CCF-STTG1 cells
were transfected with siRNA to ABCA1 (non-targeting
siRNA was used as control) in the presence of 5 μM
T1317. We found that precluding the up-regulation of
ABCA1 by T1317 with a specific siRNA also prevented
the increase in cholesterol secreted to the apoE3 media,
but it had no effect in the vector media (Figure 6C).
Together our results suggest that, via up-regulation of
ABCA1, LXR agonists can increase the lipidation of apoE,
which may improve its ability to bind and transport Ab
out of the brain.
Discussion
Genetic and biochemical evidence suggest that apoE
plays a crucial role in the pathology of AD [3,32-34]. In
the CNS, apoE is the major component of HDL-like
particles that deliver lipids to neurons via uptake by
apoE receptors such as LRP1 and LDLR. ApoE and the
cholesterol efflux pump ABCA1 are LXR-target genes
and LXRs are highly expressed in glia cells, which are
the primary site of apoE and lipid synthesis in the brain.
Both short- and long-term administration of synthetic
LXR agonists have been shown to upregulate apoE and
ABCA1 levels and to reduce brain amyloid load [17-23].
We have shown here for the first time that systemic
administration of LXR agonists also leads to a marked
and rapid up-regulation of apoE, cholesterol, and Ab
peptides in the CSF of rats, suggesting that this pathway
can contribute significantly to the elimination of Ab
from the brain.
In addition to providing cholesterol needed for synaptic
plasticity and membrane maintenance, apoE is involved
in the elimination of excess cholesterol from the brain
and this pathway is upregulated in the neurodegenerative
state [35]. In agreement with this important apoE role,
administration of LXR agonist T1317 increased brain
cholesterol excretion by almost 3-fold and slowed neuro-
degeneration in Niemann-Pick type C (NPC1) mutant
mice [36]. Deletion of LXRs in mice results in several
brain abnormalities, most notably the lateral ventricles
are closed, lined with lipid-laden cells, and deprived of
CSF content by 12 months of age [37]. Deletion of LXRs
also significantly increases brain amyloid burden in APP-
Tg mice [38]. Taken together, these studies implicate
LXRs in the clearance of excess cholesterol and Ab from
the brain, likely involving transport to the CSF.
Amyloid-binding apoE and apoAI are the most abun-
dant apolipoproteins in the CSF [39]. However, while
Figure 4 Brain ABCA1 levels were upregulated, while LDLR and VLDLR were slightly reduced by LXR agonist treatment. The brain levels
of the LXR target gene ABCA1 and of the apoE receptors LDLR and VLDLR were evaluated in RIPA extracted brain homogenates by Western blot
analysis as described in Methods. Equal amounts of supernatant proteins were loaded per lane and actin was used as an additional loading
control. A: Representative blots showing ABCA1 levels in the brain of rats treated with vehicle or LXR agonists (left panel). Densitometric analysis
of Western blots for ABCA1 (right panel). B: Representative blots showing LDLR and VLDLR steady-state levels in the brain of rats treated with
vehicle, T1317, and GW3965 for 10 days (left panel). Densitometric analysis of Western blots for LDLR and VLDLR (right panel). *p < 0.05
compared to vehicle treated controls by ANOVA, N = 4 per group.
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Figure 5 ABCA1 and apoE mRNA expression levels were upregulated in the mouse brain by LXR agonist treatment. ApoE and ABCA1
mRNA as well as protein expression were examined in the mouse brain by Western blot analysis and in situ hybridization following GW3965
treatment (50 mpk for 10 days). A: RIPA and DEA-soluble brain homogenates were prepared as described in Methods. Equal amounts of
supernatant proteins were loaded per lane and actin or ApoJ was used as an additional loading control. Densitometric analysis of Western blots
for ABCA1 (left panel) and apoE (right panel) levels in the brain of mice treated with vehicle or GW3965. *p < 0.05 compared to vehicle treated
controls by ANOVA, N = 9 per group. B: Brain distribution of apoE mRNA by in situ hybridization showing predominant astrocytic expression and
increased expression following treatment with GW3965. C: Marked increase of apoE mRNA was observed in the ependymal cells lining the lateral
ventricle following LXR agonist treatment. D: In situ hybridization for ABCA1 mRNA also showing high up-regulation in the lateral ventricle by
GW3965 (¬).
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Figure 6 LXR agonist-stimulated cholesterol efflux is apoE- and ABCA1- dependent. The role of ABCA1 in the T1317-induced cholesterol
efflux to exogenous apoE was examined in the CCF-STTG1 human astrocytoma cell line. A: HEK 293 cells were transiently transfected with
human apoE3 cDNA (E3) or empty vector (V) and concentrated serum-free conditioned media was analysed on Western blotting for apoE
content against human recombinant apoE3. B: Equal amounts of conditioned media protein containing approximately 50 μg/ml of HEK-apoE3
were added to CCF-STTG1 astrocytoma cells pre-loaded with cholesterol in serum-free media containing 5 μM T1317 or 0.05% DMSO (vehicle
control). 48 h-conditioned media was then analyzed for total cholesterol and protein content while cell monolayers were lysed for Western
blotting analysis of ABCA1 protein levels. Treatment with T1317 (5 μM) up-regulated the expression of ABCA1 and increased the release of
cholesterol to HEK-apoE3, but not to vector-HEK media. C: Knock-down of ABCA1 with specific siRNA inhibited T1317-induced ABCA1 up-
regulation and cholesterol release to HEK-apoE3 media. *p < 0.05 and **p < 0.01 by ANOVA.
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CSF apoAI is derived from the plasma, CSF apoE is
believed to originate entirely within the CNS [40]. CSF
is produced by the choroid plexus, the ependymal cells
lining the ventricles, and the brain parenchyma [41].
Besides offering support and cushion to elements of the
CNS, the CSF also provides an effective pathway for
elimination of metabolites from the brain via drainage
to the vascular system [31]. In young and adult rats,
CSF is secreted at a rate of approximately 1.3 μl/min
and is replaced in its total volume about 10 times per
day [42]. In humans, the total CSF volume is approxi-
mately 130 ml and is completely replaced about four
times per day [31]. CSF secretion rate decreases with
aging, but the overall CSF volume increases in older
individuals due to a reduced rate of turnover [42,43].
These age-related changes may translate into reduced
Ab elimination via changes in CSF fluid dynamics. We
found that apoE and ABCA1 mRNAs were highly upre-
gulated by LXR agonists in the ventricular region of the
mouse brain. In support of our findings, it has been pre-
viously shown that treatment with the endogenous LXR
ligand 24S-hydroxycholesterol led to a marked increase
in ABCA1 levels and cholesterol release from the apical
side of the rat choroid plexus epithelial cell line TR-
CSFB3 [44]. Furthermore, LXR-mediated increase in
cholesterol release was greater when apoE3 instead of
apoE4 was used as an acceptor [44]. Taken together
with these previous published findings, our results sug-
gest that LXRs play an important role in controlling the
excretion of lipid-associated apoE into the CSF and that
this mechanism may underlie changes in the ability of
the CNS to control amyloid clearance via lipid particle
transport out of the brain parenchyma.
The steady-state levels of brain ABCA1 were also
rapidly increased with LXR agonist treatment in rats,
consistently with the overall changes in apoE and cho-
lesterol seen in the CSF. The changes induced by
GW3965 treatment for ABCA1 in the mouse brain
were of similar magnitude to that observed in GW3965-
treated rats, and about 1.5-fold greater than the levels
observed in vehicle treated controls. Correspondingly
with LXR agonist treatment, a 6-fold genetic overexpres-
sion of ABCA1 in the brain led to a striking decrease of
amyloid burden in APP-Tg mice [45]. Overexpression of
ABCA1 was further associated with increased lipidation
of astrocyte-secreted apoE, but overall reduced levels of
brain apoE, suggesting that highly lipidated apoE parti-
cles have an improved clearance rate from the brain
parenchyma. In contrast, ABCA1 deletion from APP-Tg
mouse lines decreased apoE secretion by astrocytes and
brain apoE levels with concomitant increase in amyloid
deposition [46-48], further implicating apoE and lipid
transport as an important route for amyloid clearance in
the CNS.
Upon T1317 treatment, the CCF-STTG1 human
astrocytoma cell line released cholesterol to exogenously
added HEK-apoE3 conditioned media but not to HEK-
control vector conditioned media suggesting that apoE
is a putative acceptor for ABCA1-mediated cholesterol
efflux stimulated by LXR agonists. In addition, the
knock-down of ABCA1 prevented cholesterol release to
HEK-apoE in the presence of T1317. These results sug-
gest that ABCA1 up-regulation by LXR agonists leading
to increased lipidation of brain apoE could modulate
apoE’s ability to interact with Ab as well as its catabo-
lism and transport within the CNS.
ApoE is found in association with amyloid extracted
from AD brains and in vitro, apoE forms a SDS-stable
complex with Ab in an apoE isoform dependent-manner
[8,9,32]. This differential binding of apoE isoforms to Ab
appears to correlate with their ability to associate with
lipids, with apoE4 showing decreased association with
lipids and reduced ability to bind Ab when compared to
apoE3 and apoE2 [8,9]. The AD-protective apoE2 iso-
form, which has reduced binding to LDLR and increased
association with lipids compared to apoE3, can poten-
tially improve the transport of Ab out of the brain, likely
via the CSF [49] (Figure 7A). Because apoE4 appears to
have increased clearance by apoE receptors, we hypothe-
size that the diminished ability of apoE4 to bind Ab and
its faster clearance rate within the brain parenchyma
leads to impaired clearance of soluble Ab, which results
in an increased rate of oligomerization and deposition
into neuritic plaques (Figure 7B). The reduced capacity
of apoE4 to transport lipids can also lead to increased
neuronal susceptibility to toxic Ab species [50]. This
model is corroborated by previous findings showing
decreased CSF apoE in apoE4-KI mice, while human
apoE2 expressing mice have increased apoE levels in the
CSF when compared to apoE3 [51]. Furthermore, dele-
tion of LDLR in these mice normalized the level of CSF
apoE in the ε3 and ε4 genotypes to the levels observed in
the ε2 genotype, a finding that supports the in vitro evi-
dence of a faster clearance rate for apoE4 by LDLR within
the brain [11]. By increasing the levels and lipidation of
apoE as well as decreasing LDLR levels within the brain,
LXR agonists would favor the transport of apoE and amy-
loid to the CSF subsequently reducing brain amyloid bur-
den, similarly to an “apoE2 effect” (Figure 7C).
It has been previously proposed that the primary
mechanism by which LXR agonists decrease Ab burden
is via increased degradation of apoE-lipid by microglia
[22,23]. This mechanism may involve apoE receptors that
are highly expressed in microglia, particularly LDLR. In
agreement with the ability of apoE-lipid particles to bind
Ab and promote its clearance, overexpression of LDLR
reduced brain apoE levels and Ab deposition in APP Tg
mice [27]. However, LDLR deletion did not result in
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increased amyloid deposition in the same APP Tg model
[51]. Unchanged levels of amyloid could have resulted
from increased transport of apoE-bound Ab out of the
brain in the absence of LDLR. Nonetheless, due to the
high levels of Ab production in APP-Tg mice, this trans-
port mechanism was likely saturated, which prevented an
overall decrease in the brain Ab burden from occurring.
Even though LDLR is not directly regulated by LXRs,
recent findings implicated the LXR-responsive ubiqui-
tin-ligase Idol in the degradation of LDLR and VLDLR
in peripheral tissues other than the liver [52,53].
Although it did not reach statistical significance, a
down-regulation of LDLR and VLDLR levels was
observed in the brain of rats treated with LXR agonists
for 10 days, in agreement with the Idol mechanism pre-
viously described for other tissues. Taken together with
these recent findings, our results suggest that LXR ago-
nists not only increased apoE synthesis and lipidation,
but also led to reduced levels of apoE receptors in the
brain, which could result in further improvement of
Figure 7 Proposed mechanism by which LXR agonists improve apoE-mediated Ab clearance from the brain. Based on the differential
ability of the apoE isoforms to associate with lipids, Ab, and LDLR, the model predicts that the “protective” apoE2, which has poor binding to
LDLR and therefore increased association with lipids and ability to bind Ab, favors elimination of amyloid to the CSF reducing amyloid
deposition within the brain parenchyma (A). In contrast, apoE4, which has decreased association with lipids and reduced Ab binding capacity
when compared to apoE3 and apoE2, can lead to impaired Ab clearance, increased Ab oligomerization and deposition into amyloid plaques (B).
By raising the levels and the lipidation of apoE and potentially decreasing apoE receptors within the brain, LXR agonists favor the transport of
apoE and amyloid to the CSF with subsequent decrease in brain amyloid burden, similar to the “apoE2 effect” (C).
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apoE-bound amyloid clearance from the CNS. This reg-
ulatory mechanism is consistent with the pivotal role of
LXRs in promoting reverse cholesterol transport from
tissues to the liver for excretion.
Our novel findings suggest that LXRs play an impor-
tant role in the elimination of excess brain cholesterol
via secretion of apoE-lipid particles into the CSF. This
transport mechanism is also likely to be involved in the
elimination of amyloid, particularly of Ab42. It has been
recently shown that low CSF Ab42 levels are more clo-
sely linked to the presence of the ε4 allele of APOE
than to clinical status of AD patients, which suggests
that Ab42 levels in the human CSF are highly influenced
by apoE genotype [54,55]. The APOE4 ε4 genotype is
associated with increased brain amyloid load in AD
patients and normal individuals, as well as in APP Tg
mice [55,56]. Recent studies have also shown that apoE4
KI mice have decreased steady-state levels of apoE pro-
tein in the CNS when compared to apoE3 KI mice
[7,11]. Therefore, reduced levels of Ab42 in the CSF and
increased brain amyloid load in apoE4 carriers could be
explained in part by the reduced capacity of apoE4 to
bind and transport amyloid out of the brain.
Conclusions
In summary, our original findings provide new insights
into the function of LXRs in brain cholesterol homeostasis
and suggest that the CSF is likely a major pathway for
elimination of CNS-originated apoE-lipid particles and
Ab. Our results also provide further evidence to the
hypothesis that the increased risk for AD associated with
apoE4 is related to its reduced ability to associate with
lipids and therefore to bind and remove toxic Ab42 from
the CNS, supporting the rationale for the development of
safe LXR agonists for the treatment and prevention of AD.
Methods
Animals
Sprague Dawley male rats (~1 month of age) were dosed
subcutaneously with vehicle (propylene glycol) or with
synthetic LXR agonists at 30 mg/Kg (mpk) daily for 3, 6
or 10 days. T0901317 was purchased from Cayman Che-
mical and GW3965 was synthesized as previously
described [57]. CSF, plasma, and brain were collected
from non-fasted animals approximately 18 hours after
last dose. C57Bl6/SJL male mice (6 months of age) were
dosed subcutaneously with vehicle (propylene glycol) or
GW3965 at 50 mpk for 10 days. Brains were harvested
from non-fasted animals approximately 18 hours after
last dose following transcardial perfusion with ice-cold
phosphate buffer saline (PBS) containing 3 U/ml of
heparin. All animals were handled according to the Pub-
lic Health Service (PHS) Policy on Humane Care and
Use of Laboratory Animals guidelines and the study
protocol was approved by the Institutional Animal Care
and Use Committee (IACUC).
Western blotting
Rat forebrain samples including the cortex and hippo-
campus from the right hemisphere were homogenized
in 4X volume of RIPA buffer (Sigma-Aldrich) containing
complete protease inhibitor cocktail (Roche) and 1 mM
phenylmethylsulfonyl fluoride (PMSF), followed by incu-
bation with RIPA buffer for 30 additional minutes at 4°
C. One ml volume of each sample was spun at 14,000
rpm for 15 minutes at 4°C. Protein concentration was
measured in the supernatant using a BCA assay kit
(BioRad). Equal amounts of sample protein in Laemmli
buffer were separated on 4-15% Tris-HCl polyacryla-
mide SDS gels (BioRad) and transferred to polyvinyli-
dene fluoride (PVDF) membranes. Blots were placed in
blocking solution with 10% non-fat milk in phosphate
buffer saline with 0.05% Tween-20 (PBS-T) for 1 h, fol-
lowed by incubation with various primary antibodies
diluted in 5% nonfat milk in PBS-T for 3 h at room
temperature (RT) or overnight at 4°C. Primary antibo-
dies were from: Calbiochem 178479 for apoE, Signet
9080 for apoJ, Abcam ab18180 for ABCA1, R&D Sys-
tems AF2255 for LDLR, R&D Systems MAB2258 for
VLDLR, and Sigma-Aldrich A3853 for actin. Blots were
then washed with PBS-T and incubated with HRP-con-
jugated secondary antibodies at 1:2000 dilution (Amer-
sham Biosciences) for 1 h at RT. Immunoreactive bands
were visualized using ECL Plus (Amersham Biosciences)
on the Typhoon 9410 (Amersham Biosciences). Data
was analyzed using ImageQuant (Molecular Dynamics).
Undiluted rat CSF samples (1-2 μl) and 10 μl of 500-
fold diluted plasma samples were separated on 4-15%
Tris-HCl SDS-PAGE gels and transferred to PVDF
membranes. Western blots were carried out as described
above. Fresh rat CSF samples (5 μl) were also separated
on 4-16% NativePAGE Novex Bis-Tris gel (Invitrogen)
and transferred to PVDF membranes. Blots were placed
in blocking solution with 5% non-fat milk in phosphate
buffer saline with 0.1% Tween-20 (0.1% PBS-T) for 1 h,
followed by incubation with primary antibodies to apoE
(Calbiochem 178479) and to albumin (Sigma-Aldrich)
with 5% nonfat milk in 0.1% PBS-T for 1 h at RT. Blots
were washed with 0.1% PBS-T and incubated with HRP-
conjugated secondary antibodies at 1:2000 dilution for
1 h at RT. Immunoreactive bands were visualized using
SuperSignal West Femto Substrate (34095, Pierce) on
the VersaDoc Imaging System (BioRad). Data was ana-
lyzed using QuantityOne Analysis Software (BioRad).
Ab ELISA
Rat forebrain samples including the cortex and hippo-
campus from the left hemisphere were homogenized in
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4X volume of 50 mM NaCl buffer containing 0.2%
diethylamine (DEA) and complete protease inhibitor
cocktail (Roche). After homogenization, 1 ml of each
sample was boiled at 100°C for 15 min and spun at
14,000 rpm for 30 minutes at 4°C. The supernatant was
neutralized to pH 7.4 with 10% volume of 0.5 M Tris-
HCL pH 6.8. Black polystyrene plates (3925, Corning)
were coated overnight with 2 μg/ml of rodent N-term-
inal polyclonal antibody (Sig-39153, Covance) in 50 mM
carbonate-bicarbonate buffer pH 9.4 (C3041, Sigma).
Plates were washed in PBS-T and then blocked with
0.1% Tween 20-Superblock in TBS (37545, Pierce) at
RT for 3 h. For CSF Ab42 detection, 50 μl of undiluted
samples were added per well in duplicate and for CSF
Ab40, 50 μl of 5-fold diluted samples were added per
well in triplicate. For DEA-soluble brain extracts, 50 μl
of undiluted sample were added per well in quadrupli-
cate, followed by 50 μl of Ab40 G2-10 or Ab42 12F4
alkaline phosphatase-conjugated antibody. After over-
night incubation at 4°C, plates were washed and devel-
oped using alkaline phosphatase CDP-star substrate
(Applied Biosystems). Luminescence counts were mea-
sured using the LJL Analyst (Molecular Devices).
Cholesterol Measurement
Cholesterol measurement was performed using the
Amplex Red cholesterol kit according to manufacturing
instructions (A12216, Invitrogen). Briefly, the cholesterol
standard was prepared using a 5.17 mM stock solution
of cholesterol in 1X reaction buffer. 50 μl of 20-fold
diluted CSF or 50 μl of 10-fold diluted DEA brain
extracts were added per well in triplicate followed by 50
μl of the complete reaction mixture containing 150 mM
Amplex Red, 1 U/ml HRP, 1 U/ml cholesterol oxidase,
and 0.1 U/ml cholesterol esterase. The reaction mixture
was incubated at 37°C for 30 minutes and fluorescence
intensity was measured using a fluorescence microplate
reader (Molecular Devices).
In Situ Hybridization
Mouse ABCA1 cDNA was obtained from Open Biosys-
tems (Clone ID 5388972) and mouse apoE cDNA was
obtained from Invitrogen (5136415). The plasmids were
linearized with EcoRV and PvuII respectively and used to
generate antisense 35S-UTP labeled cRNA probes (1015
bp and 785 bp) for in situ hybridization [58]. Briefly, sagit-
tal 20 μm slide-mounted brain sections were fixed in 4%
paraformaldehyde, acetylated with acetic anhydride in
triethanolamine and dehydrated. Slides were then hybri-
dized overnight in a sealed humidification chamber with
the antisense riboprobe for ABCA1 or apoE mRNA, strin-
gently washed with decreasing concentrations of SSC and
treated with RNase A to remove non-specific label. After
dehydration, slides were opposed to BioMax MR x-ray
film (Kodak) for 18 hours (ABCA1) or 4 hours (apoE),
dipped in NTB-2 nuclear emulsion (Kodak) and stored
in desiccated lightproof boxes for 3 weeks (ABCA1) or
1 week (apoE) at 4°C. Slides were then developed, counter-
stained with hematoxylin, and cover-slipped. Film autora-
diographs were used to assess the regional distribution of
apoE and ABCA1 mRNA expression in the mouse brain.
Densitometric images were acquired using the MCID
image analysis system (Imaging Research Inc) and Adobe
Photoshop was used to extract images from background.
A digital camera (Nikon DSM1200C) and a slide scanning
system (Aperio ScanScope XT) were used in conjunction
with bright-field microscopy to take images of emulsion-
coated slides for evaluation of the cellular localization of
silver grains.
Cholesterol efflux assay
Human embryonic kidney (HEK) 293 cells were transi-
ently transfected with apoE3 cDNA or empty vector con-
trol using the Lipofectamine reagent (Invitrogen). After
overnight incubation, cells were rinsed three times with
pre-warmed serum-free media and incubated for 48 h in
serum-free media. Conditioned media was concentrated
using 10,000 MW cut-out Centricons (Amicon) and pro-
tein was measured using the BioRad protein assay reagent.
ApoE concentration in the media was estimated by Wes-
tern blotting against a standard curve of recombinant
human apoE3. CCF-STTG1 human astrocytoma cells
were plated in 96-well plates and incubated with media
containing 12.5 μM of cholesterol for 24 h. Cell were then
rinsed three times with pre-warmed serum-free media and
treated with serum-free media containing approximately
50 μg apoE/ml or the equivalent total protein amount of
concentrated media from empty vector-transfected HEK
cells. Following addition of 5 μM T1317 or vehicle (0.05%
DMSO), cells were incubated at 37°C for 48 h. Media was
then collected and analyzed for total cholesterol
(AmplexRed cholesterol kit, Invitrogen) and protein con-
tent (BioRad). For ABCA1 knock-down experiments,
CCF-STTG1 cells were transfected by eletrophoration
(Amaxa) with siRNA to ABCA1 or non-targeting siRNA
control (Dharmacon) prior to cholesterol loading and
addition of apoE plus 5 μM T1317 as described above.
Cell monolayers were lysed with ice-cold PBS containing
1% Triton X-100 and the protease inhibitors Complete
(Roche) and PMSF. Equal amounts of total lysate protein
were separated on SDS-PAGE and blotted with antibodies
to ABCA1 (Abcam) and actin (Sigma).
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